Literature DB >> 32380500

Unsolved Problem: (Isolated) Systolic Hypertension with Diastolic Blood Pressure below the Safety Margin.

Goran Koracevic1,2, Milovan Stojanovic3, Tomislav Kostic1,2, Dragan Lovic4, Miloje Tomasevic5, Ruzica Jankovic-Tomasevic1.   

Abstract

The problem of high systolic blood pressure (sBP) combined with low diastolic blood pressure (dBP) requires attention because sBP is directly and continuously related to the most important criterion, i.e., all-cause mortality, whereas dBP becomes inversely related to it after the age of 50-60 years. The European Society of Cardiology and European Society of -Hypertension (ESC/ESH) 2018 guidelines for hypertension (HTN) are helpful because they recommend a lower safety cut-off for in-treatment dBP. To prevent tissue hypoperfusion, these guidelines recommend that dBP should be ≥70 mm Hg during treatment. A patient with very elevated sBP (e.g., 220 mm Hg) and low dBP (e.g., 65 mm Hg) is difficult to treat if one strictly follows the guidelines. In this situation, the sBP is a clear indication for antihypertensive treatment, but the dBP is a relative contraindication (as it is <70 mm Hg, a safety margin recognized by the 2018 ESC/ESH guidelines). The dilemma about whether or not to treat isolated systolic hypertension (SH) patients with low dBP (<70 mm Hg) is evident from the fact that almost half (45%) remain untreated. This is a common occurrence and identifying this problem is the first step to solving it. We suggest that an adequate search and analysis should be performed, starting from the exploration of the prognosis of the isolated (I)SH subset of patients with a very low dBP (<70 mm Hg) at the beginning of already performed randomized clinical trials.
© 2020 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Antihypertensive treatment; Isolated systolic hypertension; Low diastolic blood pressure

Mesh:

Substances:

Year:  2020        PMID: 32380500      PMCID: PMC7445659          DOI: 10.1159/000508462

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  52 in total

1.  Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation.

Authors:  Matthew L Topel; Pratik B Sandesara; Eric P Stahl; Salim S Hayek; Ayman Samman Tahhan; Wesley T O'Neal; Yi-An Ko; Ayman Alkhoder; Mohamad Mazen Gafeer; Jonathan H Kim; Peter W F Wilson; Leslee J Shaw; Stephen E Epstein; Viola Vaccarino; Laurence S Sperling; Arshed A Quyyumi
Journal:  Int J Cardiol       Date:  2018-09-08       Impact factor: 4.164

2.  Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: population based cohort study.

Authors:  J Merlo; J Ranstam; H Liedholm; B Hedblad; G Lindberg; U Lindblad; S O Isacsson; A Melander; L Råstam
Journal:  BMJ       Date:  1996-08-24

Review 3.  The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).

Authors:  Satoshi Umemura; Hisatomi Arima; Shuji Arima; Kei Asayama; Yasuaki Dohi; Yoshitaka Hirooka; Takeshi Horio; Satoshi Hoshide; Shunya Ikeda; Toshihiko Ishimitsu; Masaaki Ito; Sadayoshi Ito; Yoshio Iwashima; Hisashi Kai; Kei Kamide; Yoshihiko Kanno; Naoki Kashihara; Yuhei Kawano; Toru Kikuchi; Kazuo Kitamura; Takanari Kitazono; Katsuhiko Kohara; Masataka Kudo; Hiroo Kumagai; Kiyoshi Matsumura; Hideo Matsuura; Katsuyuki Miura; Masashi Mukoyama; Satoko Nakamura; Takayoshi Ohkubo; Yusuke Ohya; Takafumi Okura; Hiromi Rakugi; Shigeyuki Saitoh; Hirotaka Shibata; Tatsuo Shimosawa; Hiromichi Suzuki; Shori Takahashi; Kouichi Tamura; Hirofumi Tomiyama; Takuya Tsuchihashi; Shinichiro Ueda; Yoshinari Uehara; Hidenori Urata; Nobuhito Hirawa
Journal:  Hypertens Res       Date:  2019-09       Impact factor: 3.872

4.  beta-Adrenoceptor blockade and the incidence of myocardial infarction during treatment of severe hypertension.

Authors:  I M Stewart
Journal:  Br J Clin Pharmacol       Date:  1982-01       Impact factor: 4.335

5.  Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control.

Authors:  John W McEvoy; Yuan Chen; Andreea Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin
Journal:  J Am Coll Cardiol       Date:  2016-08-30       Impact factor: 24.094

Review 6.  Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment.

Authors:  Ernesto L Schiffrin
Journal:  Am J Hypertens       Date:  2004-12       Impact factor: 2.689

Review 7.  Goals of antihypertensive therapy. Is there a point beyond which pressure reduction is dangerous?

Authors:  G Berglund
Journal:  Am J Hypertens       Date:  1989-07       Impact factor: 2.689

8.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

9.  Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

Authors:  B Williams; N R Poulter; M J Brown; M Davis; G T McInnes; J F Potter; P S Sever; S McG Thom
Journal:  J Hum Hypertens       Date:  2004-03       Impact factor: 3.012

Review 10.  Cardiovascular changes during chronic hypertensive states.

Authors:  Dorota Drozdz; Kalina Kawecka-Jaszcz
Journal:  Pediatr Nephrol       Date:  2013-09-12       Impact factor: 3.714

View more
  1 in total

1.  Do the frail experience more adverse events from intensive blood pressure control? A 2-year prospective study in the Irish Longitudinal Study on Ageing (TILDA).

Authors:  Patrick O'Donoghue; Aisling M O'Halloran; Rose Anne Kenny; Roman Romero-Ortuno
Journal:  EClinicalMedicine       Date:  2022-02-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.